StockTitan

@stocktitan.net

3 days ago

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results Lucid Diagnostics (Nasdaq: LUCD) reported 4Q25 EsoGuard revenue of $1.5M from 3,664 tests and full-year revenue of $4.706M. The company secured a national VA contract covering ~170 VA medical centers with Medicare-aligned pricing of $1,938 and reported positive real-world data showing 95% technical success and 95% of procedures under two minutes. Cash and equivalents were $34.7M at year-end. GAAP net loss was $16.3M for 4Q25 (EPS $(0.12)) and non-GAAP adjusted loss was $12.6M.

#LUCD #PAVM Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/LUCD/lucid-diagnost...

Small Cap Strategist

@smcapstrategist.bsky.social

2 months ago

Small-cap stocks in new uptrend according to average directional index, Wed Jan 7th - #QUIK #SDA #WLDN #ZNTL #AEVA #BACQ #DTI #ESQ #HYFT #ICHR #LUCD #NVAX #PGEN #SB #OGN #NSP #LPG #IHD #FC #EBS #CYD #BKSY - More: crystalequityresearch.com/leading-indi... - #smallcap

StockTitan

@stocktitan.net

2 months ago

PAVmed Announces Reverse Stock Split PAVmed (NASDAQ: PAVM) will implement a 1-for-30 reverse stock split of its common stock effective January 2, 2026 at 12:01 a.m. ET. The split-adjusted shares will begin trading on Nasdaq under the symbol PAVM at market open on January 2, 2026.The reverse split is intended to bring the company into compliance with Nasdaq's $1.00 minimum bid requirement. The company's authorized common shares will be reduced from 250,000,000 to 25,000,000. Equity awards, outstanding options, convertible securities, and ESPP allocations will be proportionately adjusted; fractional shares will be rounded up to whole shares. New CUSIP: 70387R502.

#LUCD #PAVM PAVmed Announces Reverse Stock Split

www.stocktitan.net/news/LUCD/pa-vmed-announ...

StockTitan

@stocktitan.net

3 months ago

Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection Lucid Diagnostics (Nasdaq: LUCD) reported real-world data from an 18-month retrospective analysis of 11,991 at-risk patients who underwent EsoCheck cell collection and EsoGuard DNA testing between January 2023 and June 2024.Key findings: 95% technical success, 95% of collections completed in under two minutes, and no serious adverse events. Authors concluded the results show safety, tolerability, scalability, and appropriate physician use consistent with prior studies.

#LUCD #PAVM Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection

www.stocktitan.net/news/LUCD/lucid-diagnost...

StockTitan

@stocktitan.net

4 months ago

PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results Veris Health launched commercial phase of strategic partnership and relaunched development of implantable physiological monitor. NEW YORK, Nov. 13, 2025/ PRNewswire/-- PAVmed Inc., a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the...

#LUCD #PAVM PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/LUCD/pa-vmed-provid...

StockTitan

@stocktitan.net

7 months ago

PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology PAVmed (Nasdaq: PAVM) has signed a non-binding letter of intent with Duke University to license groundbreaking endoscopic imaging technology through a new subsidiary. The technology combines angle-resolved low coherence interferometry (a/LCI) with optical coherence tomography (OCT) to identify and treat esophageal precancer during upper endoscopy.The technology, developed by Duke's Dr. Adam Wax in partnership with Dr. Nicholas Shaheen, has demonstrated 100% sensitivity and 88% overall accuracy in detecting precancerous changes. This innovative approach could replace traditional biopsies, enabling real-time detection and immediate treatment during the same endoscopic procedure.Under the proposed agreement, PAVmed's subsidiary will receive exclusive worldwide license rights to the intellectual property. The company expects this technology to complement its EsoGuard diagnostic platform and attract strategic interest from endoscopic ablation companies.

#PAVM #LUCD PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology

www.stocktitan.net/news/PAVM/pa-vmed-signs-...

StockTitan

@stocktitan.net

7 months ago

PAVmed's EsoGuard Cancer Test Hits 2,756 Q2 Tests as Medicare Coverage Decision Nears Medical device firm reports $1.2M in diagnostic test revenue, wins crucial Medicare advisory meeting for coverage decision. Subsidiary secures $16.1M funding boost. Learn more.

#PAVM #LUCD PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/PAVM/pa-vmed-provid...

StockTitan

@stocktitan.net

7 months ago

PAVmed Gets Critical 6-Month Nasdaq Extension: What This Means for Trading Status PAVmed secures crucial Nasdaq extension until January 2026 to meet minimum bid requirements. Trading continues unaffected on Nasdaq Capital Market. See compliance plan.

#PAVM #LUCD PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

www.stocktitan.net/news/PAVM/pa-vmed-grante...

StockTitan

@stocktitan.net

8 months ago

MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test Lucid Diagnostics (NASDAQ:LUCD) announced that MolDX-participating Medicare Administrative Contractors will hold a critical Contractor Advisory Committee (CAC) meeting on September 4, 2025 to evaluate Medicare coverage for its EsoGuard® Esophageal DNA Test.The virtual meeting will gather medical experts to reconsider Local Coverage Determination (LCD) L39256, following Lucid's November 2024 request. CEO Lishan Aklog highlighted the company's strong clinical evidence package and noted that nearly 40,000 patients have been referred for EsoGuard testing to date. The test's clinical utility is supported by professional society guidelines and peer-reviewed publications.

#LUCD #PAVM MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test

www.stocktitan.net/news/LUCD/mol-dx-to-conv...

StockTitan

@stocktitan.net

9 months ago

Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test Lucid Diagnostics (LUCD) has partnered with Hoag, a major California healthcare network, to implement EsoGuard® Esophageal DNA Test across its healthcare system. The partnership aims to expand access to esophageal precancer testing through Hoag's digestive health, primary care, and concierge medicine programs. Dr. Kenneth Chang, Executive Medical Director at Hoag's Digestive Health Institute, emphasized the importance of this initiative, noting that esophageal cancer incidence has increased tenfold over four decades. EsoGuard offers a quick, 3-minute non-endoscopic test to identify at-risk patients. Lucid's CEO, Dr. Lishan Aklog, views this collaboration as a significant milestone in expanding EsoGuard's accessibility within large healthcare systems and expects it to serve as a model for future partnerships.

#LUCD #PAVM Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test

www.stocktitan.net/news/LUCD/major-californ...

StockTitan

@stocktitan.net

10 months ago

Lucid Diagnostics Joins Elite Russell Indexes, Opens Door to $10.6T Investment Pool Cancer diagnostics leader gains access to $10.6T institutional benchmark. See how this Russell 2000 and 3000 inclusion impacts investment visibility. Get Details.

#LUCD #PAVM Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

www.stocktitan.net/news/LUCD/lucid-diagnost...

StockTitan

@stocktitan.net

10 months ago

PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results PAVmed (NASDAQ: PAVM) reported its Q1 2025 financial results and business updates. The company's subsidiary Lucid Diagnostics strengthened its position with $30.6M in stock offerings, ending Q1 with over $40M in proforma cash. Lucid processed 3,034 EsoGuard tests, generating $0.8M in revenue. Veris Health completed financing and resumed development of its implantable physiological monitor, preparing to launch a partnership with a major cancer center. PAVmed reported GAAP net income of $17.7M ($0.34 per share) and non-GAAP adjusted loss of $0.9M (-$0.07 per share). The company ended Q1 with $2.7M in cash, up from $1.2M in December 2024. PAVmed is now exploring expansion into the biopharma sector, actively evaluating clinical and late preclinical-stage assets.

#PAVM #LUCD PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/PAVM/pa-vmed-provid...

Small Cap Strategist

@smcapstrategist.bsky.social

10 months ago

Small-cap stocks with bullish moving average convergence divergence crossovers, Wed May 14th - #UNIT #TLS #SRDX #PAL #OMCL #LUCD #KGEI #GURE #ENSC #CLNN #BLUE #AUDC #VOC #UTZ #NCDL #KODK #CIA #ARIS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

10 months ago

Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results Lucid Diagnostics (NASDAQ: LUCD) reported its Q1 2025 financial results, processing 3,034 EsoGuard® tests and generating $0.8 million in revenue. The company strengthened its balance sheet through two stock offerings, raising $30.6 million and ending Q1 with over $40 million in proforma cash, extending runway into 2026. Operating expenses were $13.3 million, with a GAAP net loss of $36.0 million ($0.52 per share). Key developments include launching the "Embrace the Future" campaign, partnering with a major health system, and gaining traction in cash-pay concierge medicine. An NCI-sponsored study demonstrated EsoGuard's effectiveness in detecting esophageal precancer in at-risk patients without GERD, potentially increasing market opportunity by 70%. The company also secured a U.S. patent for key EsoGuard technology.

#LUCD #PAVM Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/LUCD/lucid-diagnost...

StockTitan

@stocktitan.net

11 months ago

Breakthrough: NCI Study Validates EsoGuard's Perfect Accuracy for Early Cancer Detection - $60B Market Impact New NIH-backed research reveals EsoGuard's flawless precancer detection in non-GERD patients. $8M grant fuels expanded trials targeting $60B market. See full data.

#LUCD #PAVM NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

www.stocktitan.net/news/LUCD/nci-sponsored-...

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

11 months ago

Lucid Diagnostics: DNA Testing To Get Medicare Coverage, Driving Volumes, Says Bullish Analyst A ...

www.benzinga.com/25/04/44764626/lucid-dia...

#Analyst #Color #Long […]

[Original post on benzinga.com]

StockTitan

@stocktitan.net

11 months ago

Medical Diagnostics Pioneer Lucid Secures $15M Strategic Financing Round Cancer prevention diagnostics firm prices 12.5M share offering at $1.20, backed by Canaccord Genuity. See complete financing terms and growth strategy.

#LUCD #PAVM Lucid Diagnostics Announces Pricing of Public Offering of Common Stock

www.stocktitan.net/news/LUCD/lucid-diagnost...

StockTitan

@stocktitan.net

11 months ago

Commercial-Stage Cancer Prevention Company Lucid Diagnostics Unveils Strategic Funding Move Commercial-stage cancer prevention diagnostics company seeks capital expansion. Offering includes 45-day underwriter option. Learn about strategic growth plans.

#LUCD #PAVM Lucid Diagnostics Announces Proposed Public Offering of Common Stock

www.stocktitan.net/news/LUCD/lucid-diagnost...

StockTitan

@stocktitan.net

1 year ago

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results PAVmed (NASDAQ: PAVM) reported its Q4 and full year 2024 financial results, highlighting significant progress across its subsidiaries. Lucid Diagnostics achieved record test volumes with 4,042 EsoGuard tests in Q4 (45% sequential, 84% annual increase) and $1.2 million in revenue. The company secured its first commercial insurance coverage from Highmark Blue Cross Blue Shield.Veris Health completed a private placement raising $2.4 million at a $35 million pre-money valuation, supplementing a $1.8 million NIH grant. The funds will advance their implantable physiological monitor through FDA clearance.PAVmed reported Q4 revenues from approximately 125 Veris Cancer Care Platform patients. Operating expenses were $5.2 million, including $0.7 million in stock-based compensation. The company achieved GAAP net income of $1.3 million ($0.12 per diluted share), with non-GAAP adjusted loss of $0.7 million. Cash position stood at $1.2 million, with pro forma cash of $3.6 million including Q1 2025 private placement.

#PAVM #LUCD #PAVMZ PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/PAVM/pa-vmed-provid...

StockTitan

@stocktitan.net

1 year ago

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results Lucid Diagnostics (NASDAQ: LUCD) reported strong Q4 2024 performance with record 4,042 EsoGuard tests processed, representing a 45% sequential and 84% annual increase. The company recognized $1.2 million in EsoGuard revenue for Q4 2024.Key achievements include securing over 20 new cash-pay concierge medicine contracts, obtaining first positive commercial insurance coverage from Highmark Blue Cross Blue Shield, and first agreement under state biomarker legislation with BCBS Rhode Island. The company completed a $22 million convertible debt refinancing and $15.3 million common stock financing, extending cash runway.Financial highlights show Q4 2024 operating expenses of $13.6 million, including $1.2 million in stock-based compensation. GAAP net loss was $11.5 million or $(0.20) per share. Cash position stood at $22.4 million as of December 31, 2024, with pro forma cash of approximately $36.9 million including Q1 2025 financing.

#LUCD #PAVM #PAVMZ Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/LUCD/lucid-diagnost...

StockTitan

@stocktitan.net

1 year ago

Major Breakthrough: NCCN Backs New Esophageal Cancer Testing Method, Insurance Coverage Expected to Expand NCCN endorses non-endoscopic biomarker testing for esophageal precancer detection. Landmark update validates Lucid's EsoGuard technology, potentially expanding insurance coverage.

#LUCD #PAVM Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening

www.stocktitan.net/news/LUCD/lucid-diagnost...

StockTitan

@stocktitan.net

1 year ago

Clinical Study: New EsoGuard Test Detects Esophageal Cancer Risk 140% More Effectively Peer-reviewed study validates EsoGuard's superior precancer detection, showing 2.4x better diagnostic yield. Results support insurance coverage expansion for non-invasive screening.

#LUCD #PAVM Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

www.stocktitan.net/news/LUCD/lucid-diagnost...

StockTitan

@stocktitan.net

1 year ago

Major Breakthrough: Lucid Diagnostics Secures Game-Changing Insurance Coverage for Cancer Test Highmark BCBS becomes first insurer to cover Lucid's EsoGuard DNA test for esophageal cancer screening, marking key milestone for market expansion and commercial validation.

#LUCD #PAVM Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

www.stocktitan.net/news/LUCD/lucid-diagnost...

StockTitan

@stocktitan.net

1 year ago

Lucid Diagnostics Raises $15.3 Million Through Common Stock Offering at $1.10 Per Share Cancer diagnostics firm secures funding through 13.9M share issuance to support working capital needs, with transaction expected to close March 5.

#LUCD #PAVM Lucid Diagnostics Announces $15.3 Million Registered Direct Offering

www.stocktitan.net/news/LUCD/lucid-diagnost...

StockTitan

@stocktitan.net

1 year ago

Can Lucid's Cancer Test Reach Millions More Patients? NIH Invests $8M to Find Out Five-year study targets untapped market of at-risk patients without GERD symptoms, potentially doubling EsoGuard's addressable population for esophageal cancer prevention.

#LUCD #PAVM Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD

www.stocktitan.net/news/LUCD/renowned-inves...

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

Small-cap stocks overbought with declining relative strength, Mon Feb 24th - #SLRC #OXSQ #LUCD #EH #CMRX #ACMR #YRD #XYF #EVRI #CION #BBDC - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

1 year ago

Can Lucid's New Concierge Medicine Deal Transform Its Revenue Model? Strategic partnership secures guaranteed revenue stream in fast-growing concierge healthcare market, expanding EsoGuard test accessibility through cash-pay model.

#LUCD #PAVM Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health

www.stocktitan.net/news/LUCD/lucid-diagnost...

StockTitan

@stocktitan.net

1 year ago

Lucid Diagnostics Achieves Record-Breaking Quarter with 84% Surge in EsoGuard DNA Test Volume Lucid Diagnostics reports unprecedented growth with 4,042 EsoGuard tests completed in Q4, marking 84% YoY growth as company expands through multiple revenue channels.

#LUCD #PAVM Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

www.stocktitan.net/news/LUCD/lucid-diagnost...

StockTitan

@stocktitan.net

1 year ago

Lucid Diagnostics Gets Nasdaq Extension to Meet $1 Listing Requirement Through June 2025 Lucid Diagnostics receives important 180-day extension from Nasdaq to regain $1 minimum share price compliance, maintaining listing status while pursuing recovery options.

#LUCD #PAVM Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

www.stocktitan.net/news/LUCD/lucid-diagnost...

StockTitan

@stocktitan.net

1 year ago

Lucid Diagnostics Partners with VITALExam to Screen Firefighters at High Risk of Esophageal Cancer Lucid's EsoGuard® DNA test targets firefighters' 62% higher esophageal cancer risk through strategic partnership with first responder healthcare specialist VITALExam.

#LUCD #PAVM Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

www.stocktitan.net/news/LUCD/lucid-diagnost...